Frontlight ResearchEarly access
Taking peoplePhase 3
International study on RD03/2016 eye drops compared to Leviosa® eye drops for the prevention and treatment of inflammation and the prevention of infections associated with cataract surgery in adults – FAST 7
Key facts
- Who runs it
- Ntc S.r.l.
- Where
- Greece, Italy, Poland, Spain, and Sweden28 sites in 5 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 536 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Record updated
- 13 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Signed written informed consent must be obtained before any assessment is performed
- Male or female, age ≥40 years
- Scheduled senile or presenile cataract surgery (not yet performed)
- Willing to interrupt the use of contact lenses for the entire duration of the study
- Able and willing to follow study procedures
- For females of childbearing potential, the use of highly effective contraception and agreement to use such a method during study participation
- Cataract surgery completed without complications
Who cannot take part
- Participation in previous clinical studies if less than 5 half-lives of the IMPs used have not elapsed
- Patients undergoing bilateral cataract surgery
- Patients under treatment with prostaglandin analogues or intravitreal injections of anti-VEGF (vascular endothelial growth factor) drugs
- Ocular surgery in the study eye (including laser surgery) in the 3 months before screening
- Contraindication to ocular treatment with ketorolac, dexamethasone or levofloxacin as follows: - Herpes simplex keratitis, vaccinia, varicella and other viral diseases of the cornea and conjunctiva - Fungal and mycobacterial diseases of ocular structures or untreated parasitic eye infections - Uncontrolled intraocular hypertension - Uncontrolled glaucoma - Untreated purulent infections of the eye - Acute, untreated bacterial infections
- Ocular conditions that at the discretion of the Investigator may interfere with the efficacy and/or safety evaluations (e.g. ocular herpes, blepharitis, conjunctivitis, uveitis, keratitis, diabetic retinopathy, retinal vein occlusions, retinal vasculitis, retinal angiomatous proliferation, pseudo-exfoliation syndrome, intraoperative floppy iris syndrome, etc.)
- Hypersensitivity to the products or their excipients
- Systemic diseases that may interfere with the results of the study (e.g. rheumatoid arthritis, Sjögren's syndrome, Behçet's disease, systemic lupus erythematosus, scleroderma with major ocular involvement, etc.)
- Any condition that could interfere with the correct instillation of eye drops
- Pregnancy or breastfeeding
- Monocular patients
- Visual Acuity < 20/80 of the contralateral eye measured as ETDRS or Snellen 20 feet, equal to 0.25 in decimal
This trial has no sites in United States.
It has sites in 5 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To demonstrate the non-inferior efficacy of RD03/2016 vs. Leviosa® for 7 days in the prevention and treatment of postoperative ocular inflammation.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Multicenter, randomized, double-blind, parallel-group clinical study comparing RD03/2016 (levoFloxacin and ketorolac trometAmol) eye drops vs Leviosa® (levofloxacin and dexamethaSone 21-phosphaTe) eye drops for 7 days for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults. (FAST 7)
- Record updated
- 13 November 2026